Cellectis Redirects Pipeline Toward In Vivo Gene Editing

Company Cellectis Event Type Pipeline Reprioritization (Strategic Realignment) Modality In Vivo Gene Editing (TALE-based base editing and epigenetic modulation, lipid-nanoparticle mRNA delivery) Platform .HEAL-101 (APOC3 TALE base editor) and .HEAL-201 (PCSK9 TALE epigenetic modulator) Indication Severe Hypertriglyceridemia and Severe Hypercholesterolemia Summary Cellectis will cease internal…